Impact of stent overlap on angiographic and long-term clinical outcome in patients undergoing drug-eluting stent implantation
Lorenz Räber, Peter Jüni, Lukas Löffel, Simon Wandel, Stéphane Cook, Peter Wenaweser, Mario Togni, Rolf Vogel, Christian Seiler, Franz Eberli, Thomas Lüscher, Bernhard Meier, Stephan Windecker, Lorenz Räber, Peter Jüni, Lukas Löffel, Simon Wandel, Stéphane Cook, Peter Wenaweser, Mario Togni, Rolf Vogel, Christian Seiler, Franz Eberli, Thomas Lüscher, Bernhard Meier, Stephan Windecker
Abstract
Objectives: We compared the angiographic and long-term clinical outcomes of patients with and without overlap of drug-eluting stents (DES).
Background: DES overlap has been associated with delayed healing and increased inflammation in experimental studies, but its impact on clinical outcome is not well established.
Methods: We analyzed the angiographic and clinical outcomes of 1,012 patients treated with DES in the SIRTAX (Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization) trial according to the presence or absence of stent overlap and the number of stents per vessel: 134 (13.2%) patients with multiple DES in a vessel with overlap, 199 (19.7%) patients with multiple DES in a vessel without overlap, and 679 (67.1%) patients with 1 DES per vessel.
Results: Angiographic follow-up at 8 months showed an increased late loss in DES overlap patients (0.33 +/- 0.61 mm) compared with the other groups (0.18 +/- 0.43 mm and 0.15 +/- 0.38 mm, p < 0.01). The smallest minimal lumen diameter was located at the zone of stent overlap in 17 (68%) of 25 patients with stent overlap who underwent target lesion revascularization. Major adverse cardiac events were more common in patients with DES overlap (34 events, 25.4%) than in the other groups (42 events, 21.1% and 95 events, 14.0%) at 3 years (p < 0.01). Both the risk of target lesion revascularization (20.2% vs. 16.1% vs. 9.7%, p < 0.01) and the composite of death or myocardial infarction (17.2% vs. 14.1% vs. 9.1%, p = 0.01) were increased in patients with DES overlap compared with the other groups.
Conclusions: DES overlap occurs in >10% of patients undergoing percutaneous coronary intervention in routine clinical practice and is associated with impaired angiographic and long-term clinical outcome, including death or myocardial infarction. (Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization; NCT00297661).
Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Source: PubMed